Point Therapeutics to Present at Upcoming Conferences in New York City
November 03 2006 - 7:30AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the Rodman & Renshaw 8th
Annual Healthcare Conference on Tuesday, November 7, 2006 at 9:30
a.m. Eastern Time and at the CIBC World Markets 17th Annual
Healthcare Conference on Wednesday, November 8, 2006 at 11:30 a.m.
Eastern Time. Mr. Kiepert will review key research and development
accomplishments and discuss ongoing corporate initiatives. The
Rodman and Renshaw Conference will be held at the New York Palace
Hotel, and the CIBC conference will be held at the Waldorf-Astoria.
Live Webcasts of the presentations will be available on the
Company's Web site, www.pther.com, and will be archived for 90
days. About Point Therapeutics, Inc.: Point is a Boston-based
biopharmaceutical company developing a portfolio of dipeptidyl
peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and
as vaccine adjuvants. Point is currently studying its lead product
candidate, talabostat, in two Phase 3 trials in non-small cell lung
cancer. Point is also studying talabostat in several Phase 2
trials, including as a single-agent in metastatic melanoma, in
combination with cisplatin in metastatic melanoma, in combination
with rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. Point
Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the Rodman & Renshaw 8th
Annual Healthcare Conference on Tuesday, November 7, 2006 at 9:30
a.m. Eastern Time and at the CIBC World Markets 17th Annual
Healthcare Conference on Wednesday, November 8, 2006 at 11:30 a.m.
Eastern Time. Mr. Kiepert will review key research and development
accomplishments and discuss ongoing corporate initiatives. The
Rodman and Renshaw Conference will be held at the New York Palace
Hotel, and the CIBC conference will be held at the Waldorf-Astoria.
Live Webcasts of the presentations will be available on the
Company's Web site, www.pther.com, and will be archived for 90
days. About Point Therapeutics, Inc.: Point is a Boston-based
biopharmaceutical company developing a portfolio of dipeptidyl
peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and
as vaccine adjuvants. Point is currently studying its lead product
candidate, talabostat, in two Phase 3 trials in non-small cell lung
cancer. Point is also studying talabostat in several Phase 2
trials, including as a single-agent in metastatic melanoma, in
combination with cisplatin in metastatic melanoma, in combination
with rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024